DDInter675 DDInter825
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels (K<SUB>ATP</SUB> channels) and causing depolarization of the beta cells. Compared to [glipizide], another second SU drug, glimepiride has a longer duration of action. It is sometimes classified as a third-generation SU because it has larger substitutions than other second-generation SUs. Compared to other SUs, glimepiride was associated with a lower risk of developing hypoglycemia and weight gain in clinical trials as well as fewer cardiovascular effects than other SUs due to minimal effects on ischemic preconditioning of cardiac myocytes. It is effective in reducing fasting plasma glucose, postprandial glucose, and glycosylated hemoglobin levels and is considered to be a useful, cost-effective treatment option for managing type 2 diabetes mellitus. Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM. It is commonly marketed under the brand name Amaryl as oral tablets and is typically administered once daily.
Esmolol {u} (Compound) causes {v} (Side Effect) Confusional state
Confusional state {u} (Side Effect) is caused by {v} (Compound) Glimepiride
Esmolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Esmolol {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Esmolol {u} (Compound) causes {v} (Side Effect) Confusional state
Confusional state {u} (Side Effect) is caused by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glimepiride
Esmolol {u} (Compound) causes {v} (Side Effect) Sweating increased
Sweating increased {u} (Side Effect) is caused by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Glimepiride
Esmolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Glimepiride
Esmolol {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Glimepiride
Esmolol {u} (Compound) resembles {v} (Compound) Metipranolol
Metipranolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Glimepiride
Esmolol {u} (Compound) causes {v} (Side Effect) Sticky skin
Sticky skin {u} (Side Effect) is caused by {v} (Compound) Acitretin
Acitretin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Esmolol (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Glimepiride (Compound)
Esmolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride
Esmolol (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride
Esmolol (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Gliclazide (Compound) and Gliclazide (Compound) resembles Glimepiride (Compound)
Esmolol (Compound) causes Sweating increased (Side Effect) and Sweating increased (Side Effect) is caused by Glyburide (Compound) and Glyburide (Compound) resembles Glimepiride (Compound)
Esmolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound)
Esmolol (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound)
Esmolol (Compound) resembles Metipranolol (Compound) and Metipranolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound)
Esmolol (Compound) causes Sticky skin (Side Effect) and Sticky skin (Side Effect) is caused by Acitretin (Compound) and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride